Alder Catherine M, Ambler Martin, Campbell Amanda J, Champigny Aurelie C, Deakin Angela M, Harling John D, Harris Carol A, Longstaff Tim, Lynn Sean, Maxwell Aoife C, Mooney Chris J, Scullion Callum, Singh Onkar M P, Smith Ian E D, Somers Donald O, Tame Christopher J, Wayne Gareth, Wilson Caroline, Woolven James M
Respiratory Therapy Area Unit, GlaxoSmithKline Pharmaceuticals , Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, U.K.
ACS Med Chem Lett. 2013 Aug 12;4(10):948-52. doi: 10.1021/ml400206q. eCollection 2013 Oct 10.
Inhibition of Itk potentially constitutes a novel, nonsteroidal treatment for asthma and other T-cell mediated diseases. In-house kinase cross-screening resulted in the identification of an aminopyrazole-based series of Itk inhibitors. Initial work on this series highlighted selectivity issues with several other kinases, particularly AurA and AurB. A template-hopping strategy was used to identify a series of aminobenzothiazole Itk inhibitors, which utilized an inherently more selective hinge binding motif. Crystallography and modeling were used to rationalize the observed selectivity. Initial exploration of the SAR around this series identified potent Itk inhibitors in both enzyme and cellular assays.
抑制Itk可能构成一种针对哮喘和其他T细胞介导疾病的新型非甾体治疗方法。内部激酶交叉筛选鉴定出了一系列基于氨基吡唑的Itk抑制剂。对该系列的初步研究突出了与其他几种激酶,特别是AurA和AurB相关的选择性问题。采用模板跳跃策略鉴定出一系列氨基苯并噻唑Itk抑制剂,其利用了本质上更具选择性的铰链结合基序。晶体学和建模用于合理解释观察到的选择性。围绕该系列对构效关系的初步探索在酶和细胞试验中均鉴定出了有效的Itk抑制剂。